Key Insights• According to the research report, " South Korea Antacids Market Outlook, 2031," published by Actual Market Research, the South Korea Antacids Market is anticipated to add to more than 5.01 Million by 2026-31.• South Korea is a global frontrunner in commercializing Potassium-Competitive Acid Blockers (P-CABs), fundamentally disrupting traditional OTC acid neutralizers and PPIs. Local Korean pharmaceutical firms have successfully developed and commercialized home-grown P-CAB molecules most notably HK inno.N’s tegoprazan (K-CAB), Daewoong Pharmaceutical’s fexuprazan (Fexuclue), and Onconic Therapeutics' zastaprazan (Za Q Bo). These domestic innovations provide faster, meal-independent acid control compared to legacy remedies.• Rapid urbanization, high workplace stress, late-night dining culture (e.g., chimaek / late snacks), and rising obesity rates have led to a sharp increase in acid reflux episodes across all age groups in South Korea. While clinical prevalence remains high among older demographics (around 14% in adults over 60), acid-reflux cases among young adults in their 20s surged by over 20% annually, accelerating retail self-medication purchases for quick-relief heartburn solutions.• Dual-action combinations pairing standard neutralizing salts (aluminum/magnesium salts) with sodium alginate and simethicone (anti-gas) dominate OTC pharmacy sales. Brands like Handok’s Gelfos M (aluminum phosphate suspension) and Gaviscon Double Action are staple OTC household products across the country due to their ability to provide immediate esophageal mucosal coating.Market Outlook• Traditional glass bottles and box packaging are rapidly giving way to single-dose, portable liquid stick-packs (similar to popular Korean red ginseng packaging). This format design aligns with the high mobility of Korean commuters and young professionals looking for on-the-go acidity relief.

Future product development in South Korea is heavily focusing on hybrid remedies that combine rapid acid-buffering agents with mucosal restoratives (e.g., sodium azulene sulfonate) and gastric probiotics to heal mucosal inflammation alongside fast symptom relief.• The market operates under guidelines set by the Ministry of Food and Drug Safety (MFDS) and the Korean Society of Gastroenterology (KSG), with market supply led by domestic and international leaders including HK inno.N (K-CAB), Daewoong Pharmaceutical (Fexuclue), Handok (Gelfos M), Boryung Pharmaceutical, Yuhan Corporation, and Reckitt Benckiser Korea (Gaviscon).Market DynamicsDriver: High prevalence of digestive discomfort and strong OTC/self-care cultureA major driver for South Korea's antacids market is the persistent consumer demand for products addressing indigestion, heartburn and other everyday digestive symptoms. South Korea has a well-established OTC digestive-remedies market, with consumers accustomed to using familiar products for routine digestive support. Euromonitor notes that digestive-remedy retail value sales were expected to increase in 2025, even though the category is mature and volume growth has slowed.Challenge: Mature market and substitution from digestive supplementsThe key challenge is market maturity and competition from alternative digestive-health products. Euromonitor describes South Korea's digestive-remedies category as mature, with growth slowing significantly and consumers continuing to rely on familiar products. At the same time, dietary supplements are gaining ground as alternatives to traditional digestive remedies, particularly for mild symptoms. This creates substitution pressure for conventional antacids.

Consumers may increasingly choose probiotics, digestive supplements or other wellness-oriented products rather than a conventional antacid when symptoms are mild.Trend: Shift from traditional antacids toward broader digestive-health solutionsA notable trend is the convergence of antacids with broader digestive wellness. Traditional antacid products remain important, but consumers are increasingly considering dietary supplements and other products that support digestive health over the longer term. Euromonitor specifically identifies dietary supplements as an emerging alternative to conventional digestive remedies for mild symptoms. This suggests that the competitive landscape is expanding beyond acid neutralization toward gut health, digestive balance and preventive wellness.Procurement and Industry Impact • API procurement is one of the most important issues for South Korea's pharmaceutical industry. In 2024, 392 of 545 registered pharmaceutical raw materials came from China or India, representing approximately 72% of registered raw-material pharmaceuticals. China alone accounted for 152 registrations, while India accounted for 240.

China's API imports have also risen substantially and the value of Chinese APIs imported into South Korea reached approximately US$816.3 million in 2024, up from US$678.1 million in 2018.• South Korean pharmaceutical companies have strong incentives to procure lower-cost imported APIs. Recent industry analysis reported that Chinese API imports reached KRW 1.116 trillion in 2024, while Korea's domestically produced APIs were valued at approximately KRW 4.401 trillion. Only about KRW 1.43 trillion of the domestic API production value was used in the Korean market, indicating substantial export activity. This creates a procurement trade-off: domestic API sourcing can provide greater supply security and potentially shorter lead times, but imported Chinese APIs can offer a significant cost advantage.• Because South Korea's digestive-remedies market is mature, procurement growth is unlikely to come simply from producing substantially larger volumes. Euromonitor reports that the category has experienced slowing growth, limited innovation and strong consumer reliance on familiar products, while supplements are taking some demand from conventional digestive remedies. Procurement teams should concentrate on API price optimization, packaging efficiency, contract manufacturing, inventory management and reliable supply, while R&D teams focus on higher-value formulations.

This allows manufacturers to protect margins in a mature category without relying solely on price increases.Segment AnalysisSouth Korea Antacids Market By Drug Class• Acid neutralizers remain relevant to South Korea's gastrointestinal self-care environment because they provide direct, short-term relief by neutralizing gastric acid already present in the stomach. They are particularly suited to occasional heartburn, acid indigestion and post-meal discomfort. Their role differs from prescription acid suppressants because consumers can use them primarily for immediate symptom management rather than prolonged disease control.• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-suppression position because they reduce gastric acid production rather than neutralizing existing acid. Korean prescribing data show their strong connection with GERD management: in 2020, 88.4% of PPI prescriptions in a large real-world study carried a GERD diagnosis code. This gives PPIs a stronger clinical-treatment role than conventional antacids, particularly for persistent reflux and reflux oesophagitis.• H2 antagonists provide another acid-suppression mechanism and remain relevant for selected gastrointestinal conditions. Korean real-world data show a somewhat different utilization pattern from PPIs: in 2020, 78.5% of H2-receptor-antagonist prescriptions were associated with gastritis or duodenitis, while 28.7% were associated with GERD.

This makes H2 antagonists particularly relevant to broader acid-related gastrointestinal treatment rather than being concentrated exclusively on reflux.• Pro-motility agents represent a specialized segment because their primary purpose is to influence gastrointestinal movement rather than directly neutralize or suppress acid. They may be considered when reflux symptoms coexist with delayed gastric emptying, post-meal fullness or other motility-related complaints. Their role is therefore more clinically directed than conventional antacid self-medication.• Combination formulations are particularly relevant because Korean consumers may experience overlapping heartburn, acid regurgitation, epigastric burning and dyspepsia. Combining acid-neutralizing ingredients with alginates or other gastrointestinal ingredients can provide broader symptom management. In a Korean multicenter study of 1,712 GERD patients, 37.7% had used additional OTC medication for heartburn and/or regurgitation, demonstrating demand for supplementary symptom-relief products alongside prescribed therapy.South Korea Antacids Market By Dosage Form• Tablets and chewables are well suited to South Korea's pharmacy and drugstore environment because they offer portable, standardized dosing and convenient administration. Chewable products are particularly suitable for consumers seeking relief after meals or while outside the home.

Their ease of use also makes them appropriate for occasional, symptom-triggered treatment.• Liquid suspensions provide an alternative for consumers who prefer liquid administration or have difficulty swallowing solid medicines. They allow manufacturers to combine different antacid ingredients within a single preparation. Flavour, viscosity, dose-measuring accuracy and suspension stability are important product attributes because they directly influence the user experience.• Powders provide a flexible non-tablet option that can be dissolved or dispersed before administration. Single-dose sachets can support portability and controlled dosing, making them attractive for consumers who want to carry gastrointestinal medication outside the home. However, the additional preparation step can make them less convenient than ready-to-use liquids or chewables.• Gels and syrups provide smooth administration and can support reflux-barrier formulations. Alginate-containing preparations are particularly suited to this concept because they can form a physical barrier that limits the movement of gastric contents toward the oesophagus.

Such products can therefore offer a mechanism beyond simple acid neutralization.• Gummies and other formats represent a newer consumer-oriented opportunity. Gummies can improve portability and palatability, but traditional antacid ingredients may require relatively large quantities, creating challenges around taste, texture and stability. Effervescent and rapidly dispersible products provide alternative opportunities to compete on convenience and perceived speed of action.South Korea Antacids Market By Indication• Gastroesophageal Reflux Disease (GERD) is a major indication supporting South Korea's acid-control market. A Korean population-based study using Rome III criteria found GERD in 7.1% of the population. The same study found that 50% of people with GERD also had uninvestigated dyspepsia, highlighting the substantial overlap between reflux and broader upper-GI symptoms.• Heartburn is one of the strongest consumer-facing indications because it is easily recognized and can lead to self-treatment. In a Korean multicenter study of 1,712 patients with symptomatic GERD, 37.7% had taken additional OTC medication for heartburn and/or regurgitation.

OTC use was even higher among patients with erosive reflux disease, reaching 45.8%, compared with 32.2% among patients with non-erosive reflux disease.• Peptic ulcer represents a more clinically managed indication than occasional heartburn. Acid suppression has an important role in ulcer healing and in treatment strategies involving H. pylori or medication-associated mucosal damage. Korean prescribing data demonstrate continued utilization of acid suppressants for peptic-ulcer disease: in 2020, peptic-ulcer diagnosis codes appeared in 14.7% of PPI prescriptions and 14.3% of H2-receptor-antagonist prescriptions in the analyzed dataset.• Others include dyspepsia, acid indigestion, epigastric discomfort, gastritis and post-meal digestive symptoms. A Korean population-based telephone study involving 1,044 individuals found uninvestigated dyspepsia in 12.2% of respondents, with dysmotility-like symptoms representing 56% of dyspepsia cases. This overlap makes multi-symptom gastrointestinal products particularly relevant to the Korean market.South Korea Antacids Market By Distribution Channel• Retail pharmacies remain an important channel because consumers can seek advice from pharmacists when selecting between rapid-relief antacids and longer-acting acid-suppressive products. This is particularly useful when consumers are uncertain whether recurring heartburn requires self-care or medical evaluation.

The significant OTC medication use documented among Korean GERD patients reinforces the importance of pharmacy-based symptom management.• Hospital pharmacies serve a more clinically supervised segment involving patients with diagnosed GERD, reflux oesophagitis, peptic ulcers, gastritis and other gastrointestinal disorders. Their demand is therefore driven more by physician diagnosis, hospital treatment protocols and prescription medicines than by spontaneous OTC purchasing. The high utilization of PPIs and H2 antagonists in Korean clinical practice reflects this medically directed channel.• Online pharmacies / E-commerce provide an additional route for consumers seeking convenience, repeat purchasing and product comparison. For gastrointestinal products, online purchasing can be particularly attractive to consumers already familiar with a specific antacid or heartburn-relief product. However, medicine sales remain subject to South Korea's pharmaceutical regulatory framework, so authorized distribution and product legitimacy are important considerations.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Antacids Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Drug Class• Acid Neutralizers• Proton Pump Inhibitors (PPIs)• H2 Antagonists• Pro-Motility Agents• Combination FormulationsBy Dosage Form• Tablets & Chewables• Liquid Suspensions• Powders• Gels & Syrups• Gummies & OtherBy Indication• Gastroesophageal Reflux Disease• Heartburn• Peptic Ulcer• OthersBy Distribution Channel• Retail Pharmacies• Hospital Pharmacies• Online Pharmacies / E-Commerce.